Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Therma Bright ( (TSE:THRM) ) has issued an announcement.
Therma Bright reported that its portfolio company Inretio has successfully completed the first cohort of its First-in-Human study for the PREVA Neuro-Thrombectomy System, with a positive review from the Data Safety Monitoring Board clearing the way for continued patient enrollment. The clinical data will underpin an application for a U.S. Investigational Device Exemption, with Inretio targeting a multi-center pivotal trial that could conclude within two years.
To support this next phase, Inretio is upgrading manufacturing facilities, integrating process enhancements to meet anticipated pivotal trial demand, and pursuing a capital raise to fund regulatory work, clinical operations, and scaling. Therma Bright positions the PREVA system as addressing a large and growing ischemic stroke market, underscored by rising global incidence and aging demographics, signaling potential long-term value for stakeholders if commercialization milestones are achieved.
The most recent analyst rating on (TSE:THRM) stock is a Sell with a C$0.05 price target. To see the full list of analyst forecasts on Therma Bright stock, see the TSE:THRM Stock Forecast page.
Spark’s Take on TSE:THRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:THRM is a Neutral.
The score is primarily weighed down by weak financial performance—tiny revenue scale, ongoing large losses, negative equity, and continued cash burn. Technicals are a relative positive with the price trading above key moving averages and a positive MACD, but valuation remains constrained by unprofitability and no indicated dividend support.
To see Spark’s full report on TSE:THRM stock, click here.
More about Therma Bright
Therma Bright Inc. is a Toronto-based developer and investment partner focused on advanced diagnostic and medical device technologies, with a portfolio spanning vascular health, respiratory diagnostics, and topical treatments for global healthcare markets. Its portfolio company Inretio, an Israel-based private medical device firm, is developing the PREVA neuro-thrombectomy platform to improve speed, efficacy, and access in acute ischemic stroke care.
Average Trading Volume: 52,726
Technical Sentiment Signal: Sell
Current Market Cap: C$3.19M
For an in-depth examination of THRM stock, go to TipRanks’ Overview page.